Release Date: Monday, April 4, 2016     Expiration Date: Tuesday, April 4, 2017

As a key patient advocate in acute care settings, hospital based clinicians play a major role in ensuring that appropriate measures are in place for their patients with or at high risk for serious bacterial infections. They cannot only ensure that appropriate preventive and diagnostic measures are performed, but can be an invaluable member of the interprofessional healthcare team involved in clinical decision-making. As the CDC has included specific multidrug-resistant Gram-negative bacteria and C. difficile on their list of serious healthcare threats in the US, hospital clinicians must be aware of the latest approaches to minimize the burden of these infections. This program reviews the latest evidence demonstrating how treatment selection should be guided by patient and pathogen risk factors for poor clinical outcomes. The program also highlights the role of the latest treatment approaches, including the use of newly-approved beta-lactam/beta-lactamase inhibitor combinations for serious Gram-negative infections, and novel approaches for C. difficile infection.


Optimal management of serious bacterial infections requires contributions from all healthcare professionals involved in the management of patients at risk for these infections. Therefore, this program targets hospital based clinicians who play a role in managing and preventing infections at healthcare institutions.


Upon completing this activity, participants will be able to:

  • Discuss epidemiological trends of multidrug-resistant Gram-negative bacterial infections and C. difficile infection
  • Utilize the latest evidence-based strategies for the management of serious bacterial infections based on patient and pathogen factors
  • Evaluate the role of new and novel therapeutic approaches when managing serious infections caused by Gram-negative bacteria and C. difficile


These Online Presentations are based on the CME Satellite Symposium held in conjunction with Hospital Medicine 2016, SHM’s Annual Meeting

Please Note: If you have received credit for attending the live symposium by the same name, you are not eligible to apply for credit for this online version.

This online activity is divided into three portable and easy to access episodes:

Episode 1:
Novel Approaches in the Management of
C. difficile

Stuart Johnson, MD
Episode 2:
The Growing Concern of Bacterial Infections in Hospitals: Epidemiology and Gram-Negative Resistance Mechanisms
James S. Lewis II, PharmD
Episode 3: Current Therapeutic Options for Antimicrobial-Resistant Gram-Negative Infections        
Keith A. Rodvold, PharmD


Stuart Johnson, MD
Professor, Department of Medicine
Stritch School of Medicine
Loyola University
Chicago, IL

James S. Lewis II, PharmD, FIDSA
ID Clinical Pharmacy Coordinator
& Adjunct Associate Professor
Oregon Health and Science University
Departments of Pharmacy & Infectious Diseases
Portland, OR

Keith A. Rodvold, PharmD, FCCP, FIDSA
Professor of Pharmacy Practice and Medicine
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Independent Healthcare Education and Vemco MedEd, LLC. Center for Independent Healthcare Education (Center) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center for Independent Healthcare Education designates this Enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding accreditation, please contact


Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 2 contact hours (0.2 CEUs) of continuing pharmacy education credits for participating in this activity.
ACPE UAN: UAN: 0473-9999-16-006-H01-P
Activity type: Knowledge-based


Method of Participation and Instruction for Credit

  1. Review the entire CME information including target audience, learning objectives, and disclosures.
  2. Review each episode.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.
  6. Pharmacists: Credit will be uploaded to CPE Monitor on the first of every month.

Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.




Stuart Johnson, MD has relevant financial relationships with the following commercial interests:

Advisory Board: BioK+, Summit Therapeutics, Seres Therapeutics

Dr. Johnson discusses the off-label use of following: Metronidazole, rifaximin, nitazoxanide are not FDA-approved for treating CDI, but are commonly used.  

James S. Lewis, II, PharmD has relevant financial relationships with the following commercial interests:

Advisory Board: Accelerate Diagnostics, Allergan, Astellas Pharma, The Medicines Company, and Merck & Co.

Dr. Lewis discusses the off-label use of following: Off-label use of agents for multi-drug resistant Gram-negative organisms in non-FDA-approved sites/infections.

Keith A. Rodvold, PharmD has relevant financial relationships with the following commercial interests:

Advisory Board: The Medicines Company, Melinta, Shionogi, Tetraphase, Theravance Biopharma, Zavante Therapeutics
Consultant: Rempex
Clinical Advisor: Spero Therapeutics and Zavante Therapeutics
Grant Recipient/Research Support: Theravance Biopharma
Speaker’s Bureau: Actavis/Forest Laboratories, The Medicines Company, Cubist/Merck & Co., Tetraphase
Other: Janssen Pharmaceuticals and Chimerax                                              

Dr. Rodvold discusses the off-label use of following:  Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Meropenem-RPX7009, Imipenem-Relbactam, Aztreonam-Avibactam, S649266, Plazomicin, POL7080, and BAY 41-6551.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. No (other) speakers or authors will discuss off-label use of a product.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2016 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support
This activity is supported by an educational grant from Merck & Co. 


By clicking on an Episode below, I acknowledge that I have read the entire CME information.